Madison ETFs Trust Madison Aggregate Bond ETF (ARCA: MAGG)

最新ニュース Madison ETFs Trust Madison Aggregate Bond ETF (ARCA:MAGG)

Under normal market conditions, the Fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in bonds. To keep current income relatively stable and to limit share price volatility, the Fund emphasizes investment grade securities and maintains an intermediate (typically 3-7 year) average portfolio duration, with the goal of being between 75-125% of the market benchmark duration (for this purpose, the benchmark used is Bloomberg U.S. Aggregate Bond Index, the duration of which as of June 30, 2023 was 6.31 years).

Madison Aggregate Bond ETF

Madison ETFs Trust Madison Aggregate Bond ETF

MongoDB Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects 66 cents in EPS and $519.60 million in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=MDB" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is down 37.60% over the past year, up 3.31% YTD.
Let&#8217;s look at what the charts indicate for Mongodb stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/25/03/44136446/mongodb-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">MongoDB Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
<h2 class="wp-block-heading">Mongodb Stock Strongly Bearish Ahead Of Q4 Earnings</h2>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent030525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="627" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/05114321/Screenshot-2025-03-05-at-10.08.33-PM.png" alt="" class="wp-image-810592" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/05114321/Screenshot-2025-03-05-at-10.08.33-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/05114321/Screenshot-2025-03-05-at-10.08.33-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent030525&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
MongoDB stock, at $253.40, is facing a strongly bearish trend, trading below its five-day, 20-day and 50-day exponential moving averages. The stock is also below key simple moving averages, with the eight-day at $261.47, 20-day at $276.70, 50-day at $262.53 and 200-day at $270.11 &#8211; all signaling continued downside pressure.
The Moving Average Convergence Divergence indicator at a negative 3.78 further reinforces the bearish sentiment, suggesting downward momentum remains intact.
However, there are signs of slight buying pressure, as indicated by the Relative Strength Index at 38.55. While still in bearish territory, RSI nearing 30 suggests the stock could be approaching oversold conditions, potentially setting up for a relief bounce.
Investors should watch for a break above key moving averages to confirm a shift in momentum, but until then, the technical outlook remains cautious.
<h2 class="wp-block-heading">MongoDB Analysts See 29% Upside</h2>
Ratings &amp; Consensus Estimates: <a href="https://www.benzinga.com/quote/MDB/analyst-ratings" target="_blank" rel="noreferrer noopener">The consensus analyst rating</a> on Mongodb stock stands at a Buy currently with a price target of $364.68. The latest ratings from Rosenblatt, Loop Capital and Scotiabank imply a 28.59% upside for MongoDB stock with a $325 target.
MDB Price Action: Mongodb stock was trading at $253 at the time of publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44117207/mongodb-q4-preview-in-line-or-marginally-higher-results-expected-by-bullish-analyst">MongoDB Q4 Preview: In-line Or Marginally Higher Results Expected By Bullish Analyst</a></li>
</ul>
Image via Shutterstock

Technicals

Previews

Tech

Trading Ideas

MongoDB Slides Into Q4 Earnings: Bearish Signals Vs. Wall Street Optimism

Macro Economic Events

News

Econ #s

Economics

Fed Beige Book: Overall Economic Activity Rose Slightly Since Mid-January; Overall Expectations For Economic Activity Over The Coming Months Were Slightly Optimistic; Prices Increased Moderately In Most Districts, But Several Districts Reported An Uptick

WIIM

KMDA

Kamada shares are trading higher after the company reported better-than-expected Q4 EPS results and issued FY25 revenue guidance above estimates. Additionally, the company board approved a $0.20 per share special dividend.

Last week, Apellis Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) reported a fourth-quarter earnings loss of 29 cents per share, beating the <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">consensus loss of 37 cents</a>. Sales increased 45.2% to $212.5 million, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $198.35 million</a>.
JP Morgan maintains the Overweight rating with a <a target="_blank" href="https://www.benzinga.com/quote/APLS/analyst-ratings" rel="noreferrer noopener">price forecast of $54</a>.
Analyst Anupam Rama says Apellis&#8217; lead asset, pegcetacoplan (Syfovre/Empaveli), represents a differentiated asset in the complement space, with opportunities across ophthalmology, hematology, neurology, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44038782/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">and nephrology indications</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41366153/syfovres-competitive-edge-highlights-bright-future-for-apellis-pharmaceuticals-anal" rel="noreferrer noopener">Syfovre&#8217;s Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch</a>
The company generated Syfovre sales of $167.8 million and $611.9 million for the fourth quarter and full year 2024, respectively.
Delivered approximately 94,000 Syfovre doses to physician practices in the fourth quarter, including approximately 89,000 commercial vials and 4,600 samples. More than 510,000 Syfovre injections, including clinical trials, are estimated to have been administered since launch through December 2024.
JP Morgan views Syfovre as an over $1.5 billion peak potential drug, even with conservative assumptions.
&#8220;Overall, physicians continue to use the product, driving growth, and we anticipate a fundamental and sentiment shift driving upside in APLS shares,&#8221; the analyst writes.
Analyst Rama also expects that the Empaveli C3 glomerulopathy and primary immune complex glomerulonephritis (C3G/IC-MPGN) opportunity will be a driver for Apellis stock. The company has submitted a supplemental marketing application for approval of Empaveli based on Phase 3 VALIANT results at six months; if approved, a U.S. launch is expected in 2H 2025.
Price Action: APLS stock is up 3.27% at $25.87&nbsp;at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44143705/applovin-reportedly-selling-gaming-unit-to-tripledot-studios-in-900-million-deal" target="_blank" rel="noreferrer noopener">Applovin Reportedly Selling Gaming Unit To Tripledot Studios In $900-Million Deal</a></li>
</ul>

Analyst Color

Biotech

Earnings

Health Care

Analyst Ratings

Movers

General

APLS

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Investors with a lot of money to spend have taken a bullish stance on Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with OKTA, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Okta.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 22%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $25,900, and 8, calls, for a total amount of $437,188.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $120.0 for Okta over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Okta's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Okta's whale activity within a strike price range from $50.0 to $120.0 in the last 30 days. 
<h3>Okta Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741201281_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OKTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$22.95</td>
<td>$18.8</td>
<td>$20.53</td>
<td>$88.00</td>
<td>$102.6K</td>
<td>248</td>
<td>50</td>
</tr>
<tr>
<td>OKTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$8.1</td>
<td>$7.3</td>
<td>$7.82</td>
<td>$105.00</td>
<td>$78.2K</td>
<td>1.1K</td>
<td>803</td>
</tr>
<tr>
<td>OKTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$7.5</td>
<td>$7.2</td>
<td>$7.22</td>
<td>$105.00</td>
<td>$72.2K</td>
<td>1.7K</td>
<td>1.0K</td>
</tr>
<tr>
<td>OKTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.35</td>
<td>$12.85</td>
<td>$13.35</td>
<td>$120.00</td>
<td>$53.4K</td>
<td>559</td>
<td>468</td>
</tr>
<tr>
<td>OKTA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$2.86</td>
<td>$2.54</td>
<td>$2.7</td>
<td>$108.00</td>
<td>$43.1K</td>
<td>574</td>
<td>258</td>
</tr>
</tbody>
</table>

<h3>About Okta</h3>
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Following our analysis of the options activities associated with Okta, we pivot to a closer look at the company's own performance.
<h3>Where Is Okta Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 6,195,054, with OKTA's price up by 4.42%, positioned at $113.1.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 84 days.</li>
</ul>
<h3>What Analysts Are Saying About Okta</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $117.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Susquehanna has decided to maintain their Neutral rating on Okta, which currently sits at a price target of $105. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Okta, targeting a price of $100. 
&#x2A; An analyst from WestPark Capital downgraded its action to Buy with a price target of $140. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Okta with a target price of $120. 
&#x2A; An analyst from Goldman Sachs persists with their Buy rating on Okta, maintaining a target price of $123. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Okta options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

OKTA

A Closer Look at Okta's Options Market Dynamics

Analysts' ratings for Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) over the last quarter vary from bullish to bearish, as provided by 10 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $80.9, along with a high estimate of $90.00 and a low estimate of $70.00. A decline of 4.15% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741201265_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Carrier Global. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Nigel Coe</td>
<td>Wolfe Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$76.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$77.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$87.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Carrier Global. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Carrier Global compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Carrier Global's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Carrier Global's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CARR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Carrier Global analyst ratings.</a>
<h2>Unveiling the Story Behind Carrier Global</h2>
Carrier Global manufactures heating, ventilation, and air conditioning, refrigeration, and fire and security products. The HVAC business serves both residential and commercial markets (HVAC segment sales mix is 60% commercial and 40% residential). Carrier's refrigeration segment consists of its transportation refrigeration, Sensitech supply chain monitoring, and commercial refrigeration businesses. The firm's fire and security business manufactures fire detection and suppression, access controls, and intrusion detection products. In April 2023, Carrier announced that it plans to divest its fire and security and commercial refrigeration businesses. The firm also acquired Germany-based Viessmann for approximately $13 billion.
<h3>Key Indicators: Carrier Global's Financial Health</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Carrier Global's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 19.28% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 49.55%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Carrier Global's ROE excels beyond industry benchmarks, reaching 17.73%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Carrier Global's ROA stands out, surpassing industry averages. With an impressive ROA of 6.57%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.9, Carrier Global adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARR

Where Carrier Global Stands With Analysts

Throughout the last three months, 4 analysts have evaluated BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $3.88, a high estimate of $6.00, and a low estimate of $2.50. A negative shift in sentiment is evident as analysts have decreased the average price target by 24.22%. 
<img src="https://www.benzinga.com/files/images/story/2025/1741201255_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive BRC. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>George Kelly</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.50</td>
<td>$3.50</td>
</tr>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$4.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BRC. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of BRC compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of BRC's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of BRC's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRCC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BRC analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind BRC</h2>
BRC Inc is a veteran-controlled company that serves premium coffee, content, and merchandise to active military, veterans, and first responders. it is committed to producing great coffee that consumers love, and high-quality merchandise that enables its community to showcase its brand. its omnichannel distribution has three components: Direct to Consumer channel includes its e-commerce business, through which consumers order products online and products are shipped to them, Its wholesale channel includes products sold to an intermediary such as convenience, grocery, drug, and mass merchandise stores, who in turn sell those products to consumers, and Outpost channel includes revenue from its Company-operated and franchised Black Rifle Coffee retail coffee shop locations.
<h3>Key Indicators: BRC's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, BRC faced challenges, resulting in a decline of approximately -11.51% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: BRC's net margin excels beyond industry benchmarks, reaching -2.34%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): BRC's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -17.92%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.08%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 7.34, BRC faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRCC

What Analysts Are Saying About BRC Stock

Oceaneering International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $26.25, along with a high estimate of $30.00 and a low estimate of $22.00. Witnessing a positive shift, the current average has risen by 6.4% from the previous average price target of $24.67.
<img src="https://www.benzinga.com/files/images/story/2025/1741201247_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Oceaneering International's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$27.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Oceaneering International. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Oceaneering International compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Oceaneering International's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Oceaneering International's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OII/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Oceaneering International analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Oceaneering International's Background</h2>
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
<h3>Oceaneering International's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Oceaneering International showcased positive performance, achieving a revenue growth rate of 8.99% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.
Net Margin: Oceaneering International's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.86% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.94%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Oceaneering International's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.39% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Oceaneering International's debt-to-equity ratio is below the industry average. With a ratio of 1.19, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess Oceaneering International: What You Need To Know

4 analysts have shared their evaluations of NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.0, a high estimate of $20.00, and a low estimate of $14.00. This current average reflects an increase of 24.36% from the previous average price target of $13.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1741201236_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of NeuroPace among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Osborn</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Priya Sachdeva</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NeuroPace. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of NeuroPace compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of NeuroPace's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into NeuroPace's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NPCE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NeuroPace analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About NeuroPace</h2>
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
<h3>Unraveling the Financial Story of NeuroPace</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: NeuroPace displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 28.2%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: NeuroPace's net margin excels beyond industry benchmarks, reaching -25.89%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -55.33%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): NeuroPace's ROA stands out, surpassing industry averages. With an impressive ROA of -5.72%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 7.48, NeuroPace faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NPCE

What 4 Analyst Ratings Have To Say About NeuroPace

4 analysts have expressed a variety of opinions on Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.39, a high estimate of $11.00, and a low estimate of $8.55. A decline of 5.55% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741201225_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Chimerix among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.55</td>
<td>$11.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Chimerix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Chimerix compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Chimerix's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Chimerix's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CMRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Chimerix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Chimerix's Background</h2>
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
<h3>Financial Insights: Chimerix</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Chimerix showcased positive performance, achieving a revenue growth rate of 136.36% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Chimerix's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -87996.15%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Chimerix's ROE excels beyond industry benchmarks, reaching -15.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Chimerix's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -13.57%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Chimerix's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMRX

Demystifying Chimerix: Insights From 4 Analyst Reviews

8 analysts have expressed a variety of opinions on Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $61.88, a high estimate of $66.00, and a low estimate of $54.00. Observing a 3.79% increase, the current average has risen from the previous average price target of $59.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1741201217_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Global E Online is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Kunal Madhukar</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$64.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$64.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$64.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Global E Online. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Global E Online compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Global E Online's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Global E Online's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GLBE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Global E Online analyst ratings.</a>
<h2>Unveiling the Story Behind Global E Online</h2>
Global E Online Ltd provides e-commerce solutions. The company offers a platform to enable and accelerate global, direct-to-consumer cross-border e-commerce. The platform was purpose-built for international shoppers to buy seamlessly online and for merchants to sell from, and, anywhere in the world. The company localizes the shopper experience to make international transactions as seamless as domestic ones. The platform increases the conversion of international traffic into sales by removing much of the complexity associated with international e-commerce.
<h3>Global E Online: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Global E Online's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 49.41%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Global E Online's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 0.57%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Global E Online's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.17%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Global E Online's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.12%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GLBE

What Analysts Are Saying About Global E Online Stock

Events

HOTH

Hoth Therapeutics Announces Results For HT-001

GIFT

Giftify shares are trading higher after the company launched sports ticket, merchandise savings platform.

The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) is reportedly implementing a new wave of job cuts, eliminating around 200 positions within its ABC News Group and Disney Entertainment <a target="_blank" href="https://www.benzinga.com/quote/DIS" rel="noreferrer noopener">Networks divisions.</a>
These reductions account for almost 6% of the total staff across both units, reported the<a target="_blank" href="https://www.wsj.com/business/media/disney-to-cut-nearly-6-staff-across-abc-news-disney-entertainment-networks-8af04b40" rel="noreferrer noopener"> Wall Street Journal</a>.
ABC programs, such as popular titles like &#8220;20/20&#8221; and &#8220;Nightline,&#8221; are being combined into one unit, per the report.
Also, significant adjustment is reportedly being made to Good Morning America show. The report indicates that all three hours of the program will now be managed by a single leader, replacing the current setup with separate teams for each hour.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/25/03/44143576/apples-latest-macbook-air-with-m4-chip-is-twice-as-fast-as-its-predecessor-with-lower-price" rel="noreferrer noopener">Apple&#8217;s Latest MacBook Air With M4 Chip Is Twice As Fast As Its Predecessor With Lower Price</a>
Additionally, the data-driven news platform 538 will be shut down as part of the cost-cutting measures, the report highlighted.
Since the beginning of 2023, the company has already reduced its workforce by more than 8,000 jobs, according to a report from <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-03-05/disney-cuts-6-of-abc-network-and-entertainment-tv-workforce?sref=TBDibEcD" rel="noreferrer noopener">Bloomberg</a>.
The report noted Disney has experienced a drop in both revenue and profit from its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43489835/the-walt-disney-company-reports-first-quarter-earnings-for-fiscal-2025" rel="noreferrer noopener">broadcast and cable TV sectors.</a>
In its latest quarter, Content Sales/Licensing and Other operating income increased $536 million to $312 million, driven by Moana 2&#8217;s performance.
The company has also trimmed its content budget to $23 billion, down from its <a target="_blank" href="https://www.benzinga.com/general/entertainment/25/02/43520895/disney-cuts-content-budget-by-1-billion-as-it-pushes-for-efficiency-house-of-mouse-says-too-early-to-revise-guidance-despite-earnings-beat" rel="noreferrer noopener">previous $24 billion allocation.</a>
Disney reported fiscal first-quarter 2025 revenue growth of 5% to $24.70 billion, beating the analyst estimate of $24.62 billion. Adjusted EPS of $1.76 beat the consensus <a href="https://www.benzinga.com/general/entertainment/25/02/43520895/disney-cuts-content-budget-by-1-billion-as-it-pushes-for-efficiency-house-of-mouse-says-too-early-to-revise-guidance-despite-earnings-beat">estimate of $1.45.</a>
Disney ended the quarter with 178 million Disney+ Core and Hulu subscriptions and 125 million Disney+ Core paid subscribers.
Price Action: DIS shares are trading higher by 0.05% at $109.06 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44140237/coreweave-acquires-weights-biases-to-enhance-ai-development" target="_blank" rel="noreferrer noopener">Nvidia Backed CoreWeave Acquires AI Developer Platform Weights &amp; Biases</a></li>
</ul>
Image via Shutterstock.

Entertainment

Equities

Media

Disney Cuts 200 Jobs Across ABC News And Disney Entertainment Networks: Report

Unum Group shares are trading higher after Raymond James upgraded the stock from Market Perform to Strong Buy and announced a price target of $108.

Politics

National Security Adviser Waltz Has Been Talking To His Ukrainian Counterparts; Reconsidering Funding For Ukraine; Talks On Mineral Deal Are Happening; Trump Committed To Peace Deal

TKO Group shares are trading higher after Seaport Global upgraded the stock from Neutral to Buy and announced a price target of $164.

President Trump Is Open To Hearing About Additional Tariff Exemptions

Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) shares are trading higher on Wednesday. Investors may be assessing trade policy along with President Donald Trump&#8217;s plans to make interest payments on automobile loans tax deductible for <a href="https://www.benzinga.com//node/44135215">U.S.-made vehicles.</a>
The Details: According to Reuters, the Trump administration is contemplating suspending the 25% tariff on imports from Canada and Mexico for certain products that comply with the USMCA trade agreement, which primarily affects the automotive industry.
Specifically, automakers could be granted a 30-day exemption from the tariffs. However, for the exemption to become permanent, the companies would need to demonstrate plans to invest more in U.S. automobile production.
On Tuesday, Trump met with the CEOs of Ford, General Motors, and Stellantis to discuss the potential 30-day exception. Vehicle manufacturers are open to increasing their investments in the U.S. auto sector, but they are seeking clarity on tariff policies and environmental regulations
Continued tariffs on Canadian and Mexican imports would significantly increase costs for automakers like Ford. Investors may be reacting positively to the possibility of a tariff exemption.
During his congressional address earlier this week, Trump mentioned plans to make interest payments on automobile loans tax deductible for U.S.-made vehicles, per <a href="https://www.usatoday.com/story/money/2025/03/05/trump-tax-break-car-loan-interest/81490546007/">USA Today</a>. This could incentivize consumers to purchase U.S.-made cars, potentially boosting profits for automobile makers. Investors may also be reacting positively to this potential boost.
See Also: <a href="https://www.benzinga.com/25/03/44146820/this-krystal-biotech-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday">This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday</a>
F Price Action: At the time of writing, Ford stock is moving 4.51% higher at $9.53, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

Comments

Madison ETFs Trust Madison Aggregate Bond ETF

ニュース

最新ニュース Madison ETFs Trust Madison Aggregate Bond ETF (ARCA:MAGG)

ニュース

パートナーシップ

ベンジンガ・グローバル